奥扎格雷钠联合低分子肝素钙治疗进展性脑梗死疗效观察

目的:观察奥扎格雷钠与低分子肝素钙联合治疗急性进展性脑梗死的疗效及安全性.方法:将52例急性进展性脑梗死患者随机分成观察组和对照组,各26例.对照组在临床常规治疗的基础上加用奥扎格雷钠80 mg,静脉滴注,每天2次,连用14 d;观察组在对照组基础上加用低分子肝素钙5 000 U,皮下注射,每天1次,连用1周.治疗前及治疗后第7、14天均依据美国国立卫生院卒中量表( National Institutes of Health Stroke Scale,NIHSS)评分及日常生活能力巴氏指数(Bathel index,BI)评分评定神经功能缺损程度,并监测血小板计数、出凝血时间.结果:观察组患者的NIHSS在治疗后1周、BI评分在治疗后1、2周均有明显改善,显著高于对照组(P<0.01),血小板计数、出凝血时间均在正常范围内,2组均未见明显不良反应.结论:奥扎格雷钠与低分子肝素钙联合治疗急性进展性脑梗死临床疗效好,安全性高.

Clinical effect of sodium ozagrel combined with low molecular weight heparin calcium on patients with progressive cerebral infarction

Objective:To observe the efficacy and safety of sodium ozagrel combined with low molecular weight heparin calcium on patients with progressive cerebral infarction.Methods:Fifty-two cases with acute progressive cerebral infarction were randomly divided into treatment and control groups(26 cases in each group).The patients in control group were only intravenously infused with 80mg of sodium ozagrel two times every day for 14 days on the basis of regular treatment,and the patients in treatment group were subcutaneous injected with low-molecular heparin calcium 5 000 U on the basis of control group,once a day for one week.The therapeutic effect was evaluated by National Institutes of Health Stroke Scale(NIHSS) and Bathal index(BI).Platelet count,coagulation time were detected before and after 7th and 14th day.Results:NIHSS was improved after treatment for one week,and BI scores were markedly improved after treatment one or two weeks in treatment group,which were significantly higher than those in control group(P<0.01).Platelet count,coagulation time were within normal range,there was no obvious side effect in either group.Conclusions:Sodium ozagrel combined with low molecular weight heparin calcium was an effective and safe therapy for treatment with progressive cerebral infarction.